S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,675.99 +1.22%
Next Bullish Trade
Sign in
GILD

Gilead Sciences, Inc. GILD

$134.28 -2.02 (-1.48%)
Neutral · +0.86σ
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · GILD

Momentum reads · latest daily bar
Last
$134.28
-2.02 (-1.48%)
Mkt cap
$166.7B
Healthcare
RSI(14)
56.6
neutral
Stochastic %K
69.4
neutral
MFI(14)
63.6
neutral
ADX(14)
17.6
weak trend

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $7.0B $2.0B $2.7B $2.4B 29.0% 38.7%
2025-12-31 $7.9B $2.2B $3.0B $3.1B 27.5% 37.7%
2025-09-30 $7.8B $3.1B $3.5B $4.0B 39.3% 45.0%
2025-06-30 $7.1B $2.0B $2.7B $0.7B 27.7% 38.5%
2025-03-31 $6.7B $1.3B $2.5B $1.7B 19.7% 37.3%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare GILD vs peers

Line GILD up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing GILD no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with GILD

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 0 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

No earnings history available.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
GILD ★ $167B 18.3 13.8 5.6 12.1 7.1 79.4% 4.4% 54.8% 4.76%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 43.52%

HolderShares% out
Blackrock Inc. 119,010,973 9.59%
Vanguard Capital Management LLC 80,654,776 6.50%
FMR, LLC 71,906,290 5.79%
State Street Corporation 59,858,585 4.82%
Invesco Ltd. 41,580,823 3.35%
Capital World Investors 41,283,933 3.33%
Vanguard Portfolio Management LLC 35,129,465 2.83%
JPMORGAN CHASE & CO 33,992,410 2.74%
Geode Capital Management, LLC 29,726,052 2.39%
Capital Research Global Investors 27,127,533 2.18%

Insider activity · 90d

0 buys / 6 sells · ratio 0.0 · Finnhub

  • O'Day Daniel Patrick SELL 607,133 @ $127.08
  • O'Day Daniel Patrick SELL 610,233 @ $126.09
  • Mercier Johanna SELL 124,234 @ $125.40
  • Mercier Johanna SELL 124,684 @ $124.00
  • Mercier Johanna SELL 125,754 @ $123.42
  • Dickinson Andrew D SELL 171,646 @ $125.40
  • Cain Wettan Keeley M M 19,997
  • Cain Wettan Keeley M F 5,360 @ $121.48
  • Cain Wettan Keeley M M 5,643
  • Mercier Johanna M 27,851

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$120.0
Mean
$158.2963
High
$180.0
Analysts
27
Recommendation distribution · period 2026-07-01
10
20
7
Revision trend (2026-04-01 → 2026-07-01): net 31 → 30 -1 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-07-16 FORM 4 view ·
4 2026-07-16 FORM 4 view ·
4 2026-07-02 FORM 4 view ·
4 2026-06-16 FORM 4 view ·
4 2026-06-16 FORM 4 view ·
4 2026-06-11 FORM 4 view ·
4 2026-06-11 FORM 4 view ·
4 2026-06-11 FORM 4 view ·
4 2026-06-11 FORM 4 view ·
4 2026-06-11 FORM 4 view ·
4 2026-06-02 FORM 4 view ·
4 2026-05-27 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES view ·
8-K 2026-05-20 FORM 8-K view ·
4 2026-05-18 FORM 4 view ·
4 2026-05-18 FORM 4 view ·
13F-HR 2026-05-08 Institutional holdings (13F) view ·
10-Q 2026-05-07 FORM 10-Q view ·
8-K 2026-05-07 FORM 8-K view ·
4 2026-05-04 FORM 4 view ·
4 2026-05-04 FORM 4 view ·
4 2026-05-04 FORM 4 view ·
4 2026-05-04 FORM 4 view ·
4 2026-05-04 FORM 4 view ·
4 2026-05-04 FORM 4 view ·
4 2026-05-04 FORM 4 view ·
4 2026-05-04 FORM 4 view ·
8-K 2026-05-04 FORM 8-K view ·
4 2026-04-29 FORM 4 view ·
8-K 2026-04-28 FORM 8-K view ·
4 2026-04-16 FORM 4 view ·
4 2026-04-16 FORM 4 view ·
4 2026-03-30 FORM 4 view ·
DEF 14A 2026-03-20 DEFINITIVE PROXY STATEMENT view ·
4 2026-03-17 FORM 4 view ·
4 2026-03-17 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-12 FORM 4 view ·
4 2026-03-02 FORM 4 view ·
4 2026-03-02 FORM 4 view ·
4 2026-03-02 FORM 4 view ·
4 2026-03-02 FORM 4 view ·
4 2026-03-02 FORM 4 view ·
10-K 2026-02-24 FORM 10-K view ·
8-K 2026-02-23 FORM 8-K view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-17 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES view ·
13F-HR 2026-02-12 Institutional holdings (13F) view ·
8-K 2026-02-10 FORM 8-K view ·
4 2026-02-06 FORM 4 view ·
4 2026-02-05 FORM 4 view ·
4 2026-02-05 FORM 4 view ·
4 2026-02-05 FORM 4 view ·
4 2026-01-29 FORM 4 view ·
4 2026-01-26 FORM 4 view ·
4 2026-01-21 FORM 4 view ·

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co…

Options picks · GILD

ITM + OTM ideas from the latest scan

Loading…

Congress trades · GILD

STOCK Act disclosures

Loading…

SEC filings & insiders · GILD

EDGAR · live

Loading…

Holders · GILD

Institutions & insider activity

Loading…